In Vitro Diagnostics Acquisitions from Elsevier Business Intelligence

[Elan] pays $40mm for 48.3% equity stake in [NewBridge]

Wed, 22 May 2013 19:00:57 -0400

Continuing its flurry of deal activity, [Elan Corp. PLC] is paying $40mm for a 48.3% stake in [NewBridge Pharmaceuticals Ltd.] and has the option to buy the rest of the company by 2015 for $244mm.

[OriGene] pays $16mm for life science products company [SDIX]

Thu, 25 Apr 2013 19:01:49 -0400

For $16mm, closely held [OriGene Technologies Inc.] (gene function analysis and drug discovery systems) has acquired virtually all of the assets of publicly traded analytical tools company [SDIX]. The transaction will not include SDIX’s cash (approximately $7mm at the end of Q3 2012), nor its public status--the board will review options on what to do with both.

[Thermo Fisher] in $15.2bn takeover of [Life Technologies]

Wed, 17 Apr 2013 19:01:24 -0400

After weeks of rumors, [Thermo Fisher Scientific Inc.] has finally publicly disclosed a definitive deal to acquire [Life Technologies Corp.] for $76 in cash per share (a 42% premium to the ten days prior to Life Tech’s announcement that it was conducting a strategic review), valuing the public life sciences company at $15.2bn, including $2.2bn in assumed net debt. The transaction is the largest M&A ever in the research field, surpassing Thermo Electron’s $11.8bn merger with Fisher Scientific in 2006.

[Grifols] acquires 60% of [Progenika] for €37mm

Thu, 04 Apr 2013 19:02:00 -0400

[Grifols SA] (hemotherapy, diagnostics, and hospital IV drugs) is acquiring a 60% stake in privately held diagnostics company [Progenika Biopharma SA] for €37mm ($48mm), half of which was paid in cash and the rest in 885k nonvoting Class B Grifols shares (which are traded on the Spanish Mercado Continuo and Nasdaq).

[MorphoSys] buys [Sloning BioTechnology] gaining antibody screening technology

Mon, 01 Apr 2013 19:01:18 -0400

[MorphoSys AG] has bought synthetic biology company [Sloning BioTechnology GMBH], gaining the private German biotech’s {Slonomics} fully automated genetic engineering technology for antibody screening within both therapeutic and diagnostic applications.

[Hycor Biomedical] divests its urinalysis business

Thu, 21 Mar 2013 19:01:19 -0400

[Hycor Biomedical Inc.] (diagnostics) has sold its urinalysis business to an affiliate of One Rock Capital Partners, Laurel Crown Partners, and StoneCreek Capital.

[Radiometer] buys [HemoCue AB] from [Quest] for $300mm

Thu, 14 Mar 2013 19:02:15 -0400

[Quest Diagnostics Inc.] has sold its Swedish point-of-care diagnostics division [HemoCue AB] to [Danaher Corp.]’s [Radiometer Medical APS] (acute care testing) for $300mm. The divestiture is part of Quest’s plan to realign assets and better focus on its Diagnostic Information Services business.

[Cardinal Health] buys [AssuraMed] for $2.07bn

Thu, 07 Mar 2013 19:01:29 -0500

[Cardinal Health Inc.] has acquired closely held at-home delivery and wholesale medical device company [AssuraMed] for $2.07bn on a cash- and debt-free basis.

[Viracor-IBT] buys bankrupt [Cylex]

Wed, 20 Feb 2013 19:00:56 -0500

Diagnostics company [Viracor-IBT Laboratories Inc.] has acquired [Cylex Inc.], a privately held firm that sells an immune system function test. The purchase price was not disclosed, but industry sources report that the value of the deal is less than half of the $32mm in venture funding that was put into Cylex since inception.

[Watson] buys [Uteron] for up to $305mm

Mon, 04 Feb 2013 16:09:00 -0500

[Watson Pharmaceuticals Inc.] (changing its name to [Actavis Inc.]) has acquired closely held women’s health firm [Uteron Pharma SA] for $150mm in cash up front, plus up to $155mm in earn-outs (with $45mm in near-term milestones).

[Amarantus] takes over partner [Power3 Medical]’s assets

Fri, 25 Jan 2013 19:00:59 -0500

[Amarantus BioScience Inc.] (biologics and tests for CNS and cardiovascular diseases) is acquiring all of the IP assets of its partner and now bankrupt diagnostics company [Power3 Medical Products Inc.] (formerly publicly traded) for $40k.

[MorphoSys] adds third research antibodies business with buy of [Serotec]

Mon, 14 Jan 2013 19:01:00 -0500

In an effort to further build up its [Antibodies by Design] research business, [MorphoSys AG] is acquiring privately held [Serotec Ltd.] (research antibodies and reagents) for about €29.1mm ($35.2mm): €20.5mm in cash, plus 208.6k MorpoSys shares (valued at €8.6mm).

[Immucor] buys the {Lifecodes} business from [Hologic] for $85mm plus earn-outs

Fri, 11 Jan 2013 19:02:00 -0500

[Immucor Inc.] (reagents and systems for blood transfusions) has agreed to buy the {Lifecodes} transplant diagnostics business from women’s health testing company [Hologic Inc.] Immucor will pay $85mm in cash, plus up to $10mm in achievement-based earn-outs during 2013.

[Illumina] acquires [Verinata] for $350mm

Fri, 11 Jan 2013 19:02:00 -0500

[Illumina Inc.] (diagnostics) has agreed to acquire closely held prenatal testing firm [Verinata Health Inc.] for $350mm up front, plus up to $100mm in earn-outs through 2015.

[Bio-Rad] buys [MorphoSys]'s [AbD Serotec] division for €53mm in cash

Thu, 10 Jan 2013 19:02:00 -0500

In order to focus on its therapeutic antibody business, [MorphoSys AG] is divesting its research and diagnostic antibody unit [AbD Serotec] to [Bio-Rad Laboratories Inc.] (life science research and clinical diagnostics products distributor), which will pay €53mm ($69.8mm)--over three times the AbD segment’s 2012 sales.

Warburg Pincus pays $195mm for sterile injectables maker [JHP Pharmaceuticals]

Thu, 10 Jan 2013 19:01:00 -0500

An affiliate of private equity firm Warburg Pincus is acquiring closely held [JHP Pharmaceuticals LLC] (sterile injectables) for $195mm. The management team of JHP, which is owned by Morgan Stanley Principal Investments, will continue to hold an equity stake in the acquired company.

[McKesson] acquires [PSS World Medical] for $29/share

Tue, 08 Jan 2013 19:02:00 -0500

[McKesson Corp.] will pay $29 per share (a 31% premium) to purchase all outstanding shares of fellow publicly traded medical supplies distributor [PSS World Medical Inc.] (medical devices and supplies, pharmaceuticals, healthcare information technology, and billing services). The transaction, including the assumption of $640mm in PSS outstanding debt, is valued at about $2.1bn. PSS realized $74.4mm in net income for FYE March 30, 2012, on $2.1bn in sales, and as of that date, had $163.2mm cash on hand.

[BioMarin] acquires [Zacharon] for $10mm in cash

Tue, 08 Jan 2013 19:02:00 -0500

To help strengthen its development of drug candidates for lysosomal storage diseases (LSDs), [BioMarin Pharmaceutical Inc.] (rare disease therapies) is buying glycobiology specialist [Zacharon Pharmaceuticals Inc.] for $10mm in cash plus potential earn-outs based on clinical, regulatory, and commercial achievements.

[Novartis] buys [Vivacta] for $90mm

Fri, 04 Jan 2013 19:01:00 -0500

[Novartis AG] has acquired closely held point-of-care (POC) diagnostics firm [Vivacta Ltd.] for $90mm in cash.

[Amgen] buys [deCODE genetics] for $415mm in cash

Fri, 14 Dec 2012 19:01:00 -0500

[Amgen Inc.] has acquired closely held human genetics firm [deCODE genetics EHF] for $415mm in cash.

[Paladin] acquires majority of Mexican drug company [Ativa Pharma]

Thu, 29 Nov 2012 19:01:00 -0500

Canadian drug in-licenser [Paladin Labs Inc.] has acquired the majority (50.01%) of private Mexican pharmaco [Ativa Pharma SA de CV]. At deal closing, Ativa will change its name to reflect the Paladin brand.

[Escalon] divests clinical diagnostics business to [ERBA] for $6.5mm

Mon, 01 Oct 2012 00:00:00 -0400

[ERBA Diagnostics Inc.], which is majority owned by fellow in vitro diagnostics supplier [ERBA Diagnostics Mannheim GMBH], has paid $6.5mm in cash for the clinical diagnostics business of ultrasound imaging company [Escalon Medical Corp.]

[Illumina] buys [BlueGnome]

Sat, 01 Sep 2012 00:00:00 -0400

[Illumina Inc.] has acquired [BlueGnome Ltd.], a privately held company focused on diagnostics for genetic abnormalities associated with developmental delay, cancer, and infertility.

[Danaher] pays $352mm for urinalysis firm [IRIS International]

Sat, 01 Sep 2012 00:00:00 -0400

Medical and industrial products manufacturer [Danaher Corp.] is acquiring publicly traded [IRIS International Inc.] (body fluid analysis, sample processing, and early disease detection) for $352mm, or $19.50 per share (a 51% premium).

[Metabolon] buys [Lipomics] for undisclosed amount

Wed, 01 Aug 2012 00:00:00 -0400

Biochemical profiling company [Metabolon Inc.] has acquired [Lipomics Technologies Inc.], which specializes in personalized medicine for metabolic disorders.

[BD Biosciences] acquires polymer dye company [Sirigen]

Wed, 01 Aug 2012 00:00:00 -0400

[Becton Dickinson & Co.]’s [BD Biosciences] (cell analysis and instrumentation) has acquired private polymer dye manufacturer [Sirigen Group Ltd.] Sirigen’s investors--including Seraphim Capital Fund, Oxford Capital Partners, IQ Capital, NESTA, and YFM Private Equity--realized a 2.5-4x step-up from the transaction. (Based on the £10.3mm ($16.3mm) that Sirigen has raised over its lifetime, the acquisition could be valued at £26-42mm.)

[Thermo Fisher] buys [One Lambda] for $925mm in cash

Sun, 01 Jul 2012 00:00:00 -0400

[Thermo Fisher Scientific Inc.] will pay $925mm in cash to acquire privately held transplant diagnostics firm [One Lambda Inc.] The price, which amounts to over five times the acquired company’s 2011 revenues, includes the cost of a three-year retention program for key One Lambda employees, payments to shareholders for noncompete agreements, and a one-year earn-out provision based on financial achievements.

[Luminex] acquires [GenturaDx] for $50mm in cash plus earn-outs

Sun, 01 Jul 2012 00:00:00 -0400

Biological testing company [Luminex Corp.] is paying $50mm in cash to acquire privately held [GenturaDx] (automated nucleic acid purification), which will become a wholly owned subsidiary.

[Life Technologies] scoops up [Navigenics] to strengthen its personalized medicine franchise

Sun, 01 Jul 2012 00:00:00 -0400

In an initial move to build up its molecular diagnostics business, [Life Technologies Corp.] is buying privately held personal genomics firm [Navigenics Inc.] for an undisclosed sum.

[Life Technologies] buys [Pinpoint Genomics]

Sun, 01 Jul 2012 00:00:00 -0400

[Life Technologies Corp.] has acquired [Pinpoint Genomics Inc.], a private company that develops molecular diagnostics for cancer.

[J&J]'s [Janssen-Cilag] buys cardiovascular drug developer [CorImmun]

Sat, 30 Jun 2012 08:00:00 -0400

[Johnson & Johnson]’s [Janssen-Cilag GMBH] has acquired closely held [CorImmun GMBH] (cardiovascular therapeutics) for money up front and an earn-out based on a clinical milestone.

[Wuhan Humanwell Healthcare] buys 80% of [Beijing Baron Medical] for RMB776mm

Wed, 27 Jun 2012 08:00:00 -0400

Diversified Chinese pharmaceutical distributor [Wuhan Humanwell Healthcare Co. Ltd.] has bought from holding company Wuhan Modern Technology Group, 80% of privately held in vitro diagnostics and IVD equipment distributor [Beijing Baron Medical Equipment Co. Ltd.] (Baron), paying RMB776mm ($122.6mm). Humanwell financed the transaction with a concurrent RMB1.025bn private placement.

[LabCorp] pays $244mm for toxicology testing company [Medtox Scientific]

Fri, 08 Jun 2012 08:00:00 -0400

[Laboratory Corp. of America Holdings] has acquired publicly traded [Medtox Scientific Inc.] (lab testing services and drug screening diagnostics) for $244mm, or $27 per share in cash (a 35% premium).

[Qiagen] buys private next-generation sequencing firm [Intelligent Bio-Systems]

Fri, 01 Jun 2012 00:00:00 -0400

In a move into the next-generation sequencing (NGS) arena, [Qiagen NV] (nucleic-acid-based technologies) has acquired privately held [Intelligent Bio-Systems Inc.] (IBS), which is developing NGS instruments for applications in clinical research and molecular diagnostics.

[Agilent] to pay $2.2bn for [Dako AS]

Sat, 19 May 2012 08:00:00 -0400

Expanding its presence in the diagnostics market, life sciences company [Agilent Technologies Inc.] will pay $2.2bn in cash to buy [Dako AS] (cancer testing) from private equity firm EQT Partners.

[Qiagen] buys obstetric assay company [AmniSure International]

Fri, 18 May 2012 08:00:00 -0400

[Qiagen NV] (diagnostics) has agreed to acquire privately held obstetric assay developer [AmniSure International LLC].

PE firm Linden Capital Partners buys [SeraCare Life Sciences] for $80.8mm

Fri, 11 May 2012 09:53:00 -0400

After months of negotiations, an affiliate of private equity outfit Linden Capital Partners has acquired publicly held [SeraCare Life Sciences Inc.] (diagnostic controls, plasma-derived reagents, and molecular biomarkers).

[Hologic] to pay $3.75bn in cash for [Gen-Probe]

Fri, 04 May 2012 08:00:00 -0400

In a move to become the largest diagnostics company focused on women’s health, [Hologic Inc.] is acquiring all the outstanding shares of fellow public company [Gen-Probe Inc.] (molecular diagnostics) for $82.75 each in cash (a 22% premium), valuing the transaction at $3.75bn.

[Biota Holdings], [Nabi Biopharmaceuticals] plan to merge and create public US-based company; terms revised

Fri, 27 Apr 2012 09:41:00 -0400

Australian firm [Biota Holdings Ltd.] is planning to merge with fellow public vaccines developer [Nabi Biopharmaceuticals] (based in the US) to create a new Nasdaq-listed company, [Biota Pharmaceuticals Inc.], which will have headquarters in Rockville, MD.

[Abingdon Health] takes a 50.1% equity stake in [Molecular Vision Ltd.]

Sat, 21 Apr 2012 08:00:00 -0400

[Abingdon Health Ltd.] has purchased a 50.1% equity stake in fellow private diagnostics firm [Molecular Vision Ltd.]

[Grifols] acquires majority of Spanish therapeutics and diagnostics company [Araclon]

Wed, 04 Apr 2012 08:00:00 -0400

Through its Gri-Cel SA investment arm, plasma derivatives producer [Grifols SA] has acquired 51% of fellow Spanish company, privately held therapeutics and diagnostics firm [Araclon Biotech SL].

[Abcam] pays $155mm for monoclonal antibody producer [Epitomics]

Thu, 29 Mar 2012 08:00:00 -0400

[Abcam PLC] has acquired fellow antibody research tools company, privately held [Epitomics Inc.], for $155mm. Half of the sum will be paid in cash, with the rest in the form of approximately 14.7mm Abcam shares (based on the pre-announcement ten-day average of £3.34 ($5.29)).

[Alere] buys [eScreen] for $270mm in cash, up to $70mm in earn-outs

Wed, 14 Mar 2012 08:00:00 -0400

Point-of-care diagnostics company [Alere Inc.] has acquired private drugs-of-abuse screening firm [eScreen Inc.] for $270mm in cash up front, plus another $70mm in earn-outs.

[Alere] pays $84.6mm, plus earn-out, to buy diabetes supply company [Arriva]

Wed, 14 Mar 2012 08:00:00 -0400

[Alere Inc.] has acquired diabetes testing supplies company [Arriva Medical LLC]--a closely held company owned by private equity investment firm Palm Beach Capital--for $64.4mm in cash and 806k Alere restricted common shares valued at $20.2mm (based on Arriva’s ten-day average). Arriva shareholders are also eligible for a $3.4mm earn-out if certain operational goals are met by June 30, 2012.

[Trinity Biotech] buys [Fiomi Diagnostics] for $13.1mm in cash, stock, and earn-outs

Fri, 09 Mar 2012 08:00:00 -0500

[Trinity Biotech PLC] (point-of-care and clinical laboratory diagnostics) has acquired [Fiomi Diagnostics AB] for $13.1mm, with $9.7mm up front ($5.6mm will be in cash and $4.1mm in 408k Trinity Biotech ADRs) and $3.4mm in earn-outs (for getting the CE Mark, FDA submission, and FDA approval of a troponin I assay).

[Alere] finalizes acquisition of [Axis-Shield] at increased price

Fri, 09 Mar 2012 08:00:00 -0500

In a hostile takeover process that began in July, point-of-care diagnostics firm [Alere Inc.] has acquired a 94.18% stake in publicly traded [Axis-Shield PLC] (clinical lab and point-of-care diagnostics) in a cash transaction worth £221mm ($356mm), paying £4.70 ($7.56) per share--a 45% premium to Axis-Shield’s July pre-announcement price. At the offer’s commencement, Alere had already owned 2.23%.

[Sigma-Aldrich] pays $350mm for testing services company [BioReliance]

Thu, 23 Feb 2012 08:00:00 -0500

Private equity firm Avista Capital Partners is selling [BioReliance Corp.], a private CRO, to [Sigma-Aldrich Corp.] (life science product distributor) for $350mm in cash. BioReliance will become part of the [Sigma-Aldrich Fine Chemicals] (SAFC) subsidiary, which supplies large-scale organic chemicals and biochemicals for biopharma, diagnostic, industrial, and electronics development and production.

[Signal Genetics] acquires [ChipDx]

Thu, 16 Feb 2012 08:00:00 -0500

Predictive testing company [Signal Genetics LLC] has acquired privately held [ChipDX LLC] (molecular diagnostics for cancer) for an undisclosed sum.

[Roche] in hostile takeover of next-gen sequencing company [Illumina] worth $5.5bn; withdrawn

Sat, 28 Jan 2012 08:00:00 -0500

Publicly traded [Illumina Inc.] (gene variation and function analysis) has received an unsolicited proposal to be acquired by [Roche] for $5.5bn, or $44.50 in cash per share, a 64% premium to the ten-day average prior to December 21, which is when rumors surfaced about a potential deal between the companies.

[Roche] acquires platelet testing specialist [Verum] for €11mm plus earn-outs

Fri, 09 Dec 2011 08:00:00 -0500

[Roche Professional Diagnostics] (RPD) is paying €11mm ($15mm) up front in cash for privately held [Verum Diagnostica GMBH] (laboratory coagulation analysis), which is owned by German medtech company [Dynabyte Informationssysteme GMBH]. Verum could also receive €2mm in earn-outs based on its performance.

[Affymetrix] to acquire [eBioscience] for $330mm cash; companies later decide on $315mm

Mon, 05 Dec 2011 11:13:00 -0500

Genetic analysis company [Affymetrix Inc.] has signed a definitive agreement to buy private [eBioscience Inc.] (oncology and immunology flow cytometry reagents) for $330mm in cash.

[Opko Health] pays $30mm plus earn-outs to acquire [Claros Diagnostics]

Fri, 21 Oct 2011 08:00:00 -0400

[Opko Health Inc.] (drugs and diagnostics) has acquired privately held point-of-care testing company [Claros Diagnostics Inc.] Opko paid $10mm in cash and issued $20mm of its equity (4.5mm common shares at $4.45 apiece; market average); it could also hand over up to $19mm in shares as earn-outs for achieved milestones.

[Zynex] signs preliminary transaction to buy [NeuroDyne Medical]

Tue, 20 Sep 2011 08:00:00 -0400

Diagnostic and monitoring device company [Zynex Inc.]’s [Zynex NeuroDiagnostics Inc. ](ZND; neurosensors) division has signed a letter of intent to acquire privately held [NeuroDyne Medical Corp.]

[PerkinElmer] buys [Caliper Life Sciences] for $557mm in cash

Fri, 16 Sep 2011 08:00:00 -0400

[PerkinElmer Inc.] (diagnostics and analytical instruments) has agreed to buy [Caliper Life Sciences Inc.] (molecular imaging and detection technologies) for about $557mm in cash. Caliper shareholders will receive $10.50 per share, a 46% premium.

[OraSure Technologies] buys [DNA Genotek] for $53mm in cash

Fri, 19 Aug 2011 08:00:00 -0400

[OraSure Technologies Inc.] (oral fluid diagnostic devices) has acquired closely held molecular diagnostics company [DNA Genotek Inc.] for $53mm in cash. DNA Genotek will function as a wholly owned subsidiary.

[Argene] acquired by [bioMerieux] for €37.5mm

Thu, 18 Aug 2011 08:00:00 -0400

[Institut Merieux]’s [bioMerieux SA] has purchased molecular diagnostics firm [Argene SA] for €37.5mm ($52.8mm) up front and up to €5mm in contingent payments.

[Roche] to pay €130mm up front for cervical cancer diagnostics developer [mtm]

Fri, 29 Jul 2011 08:00:00 -0400

[Roche] is paying €130mm up front ($180mm) and up to €60mm in performance-related earn-outs for private cervical cancer testing company [mtm Laboratories AG], which will become a division of the Big Pharma’s tissue-based diagnostics unit [Ventana Medical Systems Inc.] (part of [Roche Diagnostics]).

[Hologic] buys [TCT] for $135mm cash, plus earn-out

Fri, 22 Jul 2011 08:00:00 -0400

[Hologic Inc.] (women’s health diagnostics and medical imaging systems) has acquired private Chinese diagnostics distributor [TCT International Co. Ltd.] for $135mm in cash ($35mm of which will be paid on the one-year anniversary), plus a cash earn-out equal to a multiple of TCT’s increasing revenue growth (continent upon its performance over the next two years).

[Immucor] taken private through $1.9bn TPG buy-out

Sat, 16 Jul 2011 08:00:00 -0400

Investment funds managed by TPG Capital will pay $27 per share in cash (a 36% premium) to buy reagent developer [Immucor Inc.] The deal is valued at about $1.9bn.

[Luminex] pays $34mm to buy [EraGen Biosciences]

Wed, 29 Jun 2011 08:00:00 -0400

[Luminex Corp.] ({xMAP} and {xTAG} multiplex platforms for bioassay production) has acquired private molecular reagent manufacturer [EraGen Biosciences Inc.] for $34mm in cash.

[Qiagen] acquires stake in [Ipsogen]

Wed, 22 Jun 2011 15:15:00 -0400

Sample and assay technologies developer [Qiagen NV] has offered €12.90 ($18.63, a 71% premium) per share to acquire 47% of public molecular diagnostics firm [Ipsogen SA]. Immediately following the signing of a definitive agreement and the commencement of the initial purchase, Qiagen will begin the process of acquiring the remaining 53% of Ipsogen. The total value of the deal is €65mm based on 5mm shares outstanding.

[Health Diagnostic Laboratory] buys [Harris Scientific]

Mon, 20 Jun 2011 12:45:00 -0400

[Health Diagnostic Laboratory Inc.] (HDL; biomarkers for cardiovascular and other diseases) has acquired [Harris Scientific Inc.], a closely held company that provides omega-3 fatty acid testing.

[Cell Biosciences] to acquire [Protein Forest] for $5.25mm in stock swap

Wed, 15 Jun 2011 08:00:00 -0400

Protein analysis company [Cell Biosciences Inc.] has acquired privately held [Protein Forest Inc.] (proteomics tools) for $5.25mm in Series E preferred shares in exchange for Protein Forest outstanding senior notes.

[Nestle] boosts personalized nutritionals initiative with [Prometheus] buy

Fri, 03 Jun 2011 08:00:00 -0400

In a deal that one Bank Vontobel analyst estimated at $567mm-1bn, [Nestle Health Science SA], a newly formed division of [Nestle SA], has acquired privately held [Prometheus Laboratories Inc.] (drug and diagnostic in-licenser).

[Lab21] pays undisclosed amount for [Myconostica]

Fri, 03 Jun 2011 08:00:00 -0400

Personalized medicine company [Lab21 Ltd.] has further expanded its infectious disease portfolio through the purchase of privately held [Myconostica Ltd.] (molecular diagnostics to detect invasive fungal infections) for an undisclosed sum.

[Thermo Fisher] pays €2.46bn for [Phadia]

Wed, 25 May 2011 08:00:00 -0400

[Thermo Fisher Scientific Inc.] has agreed to pay €2.46bn ($3.46bn) in cash to buy Swedish in vitro diagnostics company [Phadia AB] from the private equity firm Cinven. Phadia will receive €1.052bn in cash, and the remainder will be used to repay debt.

[Rules-Based Medicine] acquires [Satoris] assets

Tue, 24 May 2011 08:00:00 -0400

Just weeks ahead of closing its acquisition by [Myriad Genetics Inc.], [Rules-Based Medicine Inc.] (RBM; biomarker testing and diagnostics) has purchased all of the intellectual property assets of privately held [Satoris Inc.], which is developing an Alzheimer’s diagnostic.

[Myriad Genetics] pays $80mm cash for [Rules-Based Medicine]

Sat, 30 Apr 2011 08:00:00 -0400

To create what it hopes will be a new leading companion diagnostics developer, [Myriad Genetics Inc.] (molecular diagnostics) has acquired private biomarker testing laboratory [Rules-Based Medicine Inc.] for $80mm in cash.

[LabCorp] buys [Orchid Cellmark] for $85.4mm

Fri, 15 Apr 2011 08:00:00 -0400

[Laboratory Corp. of America Holdings] has purchased fellow diagnostics firm [Orchid Cellmark Inc.] for $2.80 per share (a 40% premium) in cash, or a total of $85.4mm.

[Qiagen] offers to buy [Cellestis] for $355mm, later ups offer

Tue, 05 Apr 2011 08:00:00 -0400

Molecular diagnostics company [Qiagen NV] is proposing to buy public Australian diagnostics firm [Cellestis Ltd.] for A$341mm ($355mm) in cash, or $3.69 per share (a 25% premium).

[Quest Diagnostics] buys [Celera]

Fri, 25 Mar 2011 08:00:00 -0400

[Quest Diagnostics Inc.] has acquired [Celera Corp.] for $671mm, or $344mm net of Celera’s $327mm in cash and investments. Shareholders received $8 per share (a 28% premium).

[Roche] buys German lab automation company [PVT] for €65mm

Fri, 18 Mar 2011 12:25:00 -0400

[Roche Professional Diagnostics] (RPD) is acquiring private German company [PVT Probenverteiltechnik GMBH] (automated solutions for clinical diagnostic laboratories) for €65mm ($91mm) up front, plus as much as €20mm in performance-based earn-outs. The deal also includes PVT’s US distribution subsidiary [PVT Lab Systems LLC].

[Thermo Fisher] sells [Athena Diagnostics] to [Quest] for $740mm

Tue, 01 Mar 2011 08:00:00 -0500

[Thermo Fisher Scientific Inc.] is divesting its esoteric and genetic testing division [Athena Diagnostics Inc.] to [Quest Diagnostics Inc.] for $740mm. Thermo has concurrently sold another subsidiary--[Lancaster Laboratories]--to [Eurofins Scientific] for $200mm.

[Eurofins] acquires [Lancaster Labs] from [Thermo Fisher] for $200mm

Tue, 01 Mar 2011 08:00:00 -0500

[Thermo Fisher Scientific Inc.] has sold its analytical services division [Lancaster Laboratories Inc.] to [Eurofins Scientific SE] (primarily cGMP quality control services) for $200mm, subject to post-closing adjustments.

[Danaher] takes over [Beckman Coulter] in deal worth $6.8bn

Sat, 12 Feb 2011 08:00:00 -0500

In its latest deal that adds more instrumentation offerings, [Danaher Corp.] (testing and analytical systems, dental technologies, and diagnostics) is acquiring public biomedical testing company [Beckman Coulter Inc.] for $83.50 per share (a 47% premium to the ten-day average prior to December 9, 2010, when the takeover was rumored). Including Beckman’s 70.9mm shares outstanding, plus the assumption of debt and net cash, the transaction is valued at $6.8bn.

[Trinity] buys [Phoenix Biotech] for $2.5mm

Thu, 10 Feb 2011 08:01:00 -0500

[Trinity Biotech PLC] is acquiring fellow diagnostics firm [Phoenix Biotech Corp.] for $2.5mm in cash--$1mm up front and the remaining to be paid over the next 12 months.

[Novartis] buys [Genoptix] for $440mm

Fri, 28 Jan 2011 08:00:00 -0500

[Novartis AG] has agreed to buy publicly traded [Genoptix Inc.] (laboratory testing) for $440mm in cash, or $25 for each share (a 25% premium).

[Caliper] takes over [Cambridge Research & Instrumentation] in $20mm deal

Tue, 18 Jan 2011 12:01:00 -0500

[Caliper Life Sciences Inc.] (drug discovery tools) has bought [Cambridge Research & Instrumentation Inc.], a privately held maker of optical imaging systems, in a transaction valued at $20mm, in which Caliper will pay $7.9mm cash, issue 1.65mm of its own shares worth $10.3mm, and assume $1.8mm of Cambridge’s debt.

[PerkinElmer] buys molecular imaging technology company [VisEn]

Tue, 11 Jan 2011 08:00:00 -0500

To expand its cellular imaging business, [PerkinElmer Inc.] has acquired privately held in vivo molecular imaging technology company [VisEn Medical Inc.]

[Gen-Probe] pays $53mm in cash for [GTI Diagnostics]

Sat, 18 Dec 2010 08:03:00 -0500

Molecular diagnostics firm [Gen-Probe Inc.] is strengthening its transplant testing business through the $53mm cash purchase of privately held [GTI Diagnostics].

[Transgenomic] buys [Clinical Data]'s {Familion}, {PGxPredict}

Fri, 17 Dec 2010 08:03:00 -0500

[Transgenomic Inc.] (genetic variation and mutation analysis tests) has agreed to purchase [Clinical Data Inc.]'s (mainly cardiovascular diseases and CNS disorders) {Familion} testing and {PGxPredict} pharmacogenomics biomarker development business for $15.4mm, comprised of $6mm in cash, a three-year 10% note for $8.5mm, and a one-year 6.5% note for $932k.

[Glaxo] spends $70mm for Chinese urology specialist [MeiRui]

Sat, 11 Dec 2010 08:03:00 -0500

[GlaxoSmithKline PLC] has paid $70mm in cash for [Nanjing MeiRui Pharma Co. Ltd.], a private drug, device, and diagnostic company based in China.

[Sekisui Chemical] pays $265mm in cash for [Genzyme Diagnostics]

Thu, 25 Nov 2010 08:03:00 -0500

Japanese pharmaco [Sekisui Chemical Co. Ltd.] is paying $265mm in cash to acquire [Genzyme Corp.]'s [Genzyme Diagnostics].

[OncoVista] divests [AdnaGen]

Sat, 20 Nov 2010 08:03:00 -0500

[OncoVista Innovative Therapies Inc.] (cancer biomarkers and personalized therapeutics) is selling the 78% that it owns of its [AdnaGen AG] (mainly biomarkers) subsidiary to investment holding company Alere Holdings Bermuda Ltd. Canon's Court.

[Thoratec] sells [International Technidyne] for $55mm in cash

Thu, 18 Nov 2010 08:03:00 -0500

[Thoratec Corp.] (advanced-stage heart failure devices) has sold [International Technidyne Corp.] (ITC; hemostasis management and point-of-care (POC) testing products) to an affiliate of Warburg Pincus for $55mm in cash.

[Eli Lilly] to buy [Avid] for $300mm up front plus earn-outs

Thu, 11 Nov 2010 08:03:00 -0500

[Eli Lilly & Co.] has agreed to pay $300mm up front to acquire privately held [Avid Radiopharmaceuticals Inc.], a developer of molecular imaging agents that detect and monitor various diseases.

[GE] to buy [Clarient] for $587mm

Tue, 26 Oct 2010 16:34:00 -0400

[GE Healthcare] has signed a definitive agreement to acquire public molecular diagnostics firm [Clarient Inc.] The deal is valued at about $587mm, with GE paying $5 in cash for every common share outstanding (a 39% premium) and $20 for each preferred share.

[Volition] buys [ValiBIO] from [ValiRx] for $1mm

Sat, 09 Oct 2010 07:57:00 -0400

[ValiRx PLC] has divested its [ValiBIO SA] diagnostics division to fellow cancer test developer [Singapore Volition Pte. Ltd.] for $1mm, of which $400k will be paid in cash (in four equal installments) and the remainder in Volition shares.

[LabCorp] to pay $925mm cash for [Genzyme Genetics]

Fri, 17 Sep 2010 07:57:00 -0400

[Laboratory Corp. of America Holdings] is acquiring esoteric testing specialist [Genzyme Genetics] for $925mm in cash.

Investment firm Ramius attempts to buy [Cypress Bioscience]

Thu, 02 Sep 2010 07:57:00 -0400

Affiliates of Ramius LLC, an investment management firm owned by Cowen Group, have made an unsolicited offer to acquire the 90.1% of publicly traded [Cypress Bioscience Inc.] (rheumatoid arthritis diagnostics and CNS drugs) that it doesn't already own for $138.3mm, or $4 per share (an 80% premium). Cypress is asking shareholders not to take any action at this time.

[Sanofi] launches $69 per share bid for [Genzyme]; $17.5bn value

Wed, 01 Sep 2010 07:57:00 -0400

Confirming speculation that began over a month ago, [Sanofi-Aventis] has made public a non-binding offer to acquire [Genzyme Corp.] The Big Pharma says it will pay $69 for each of Genzyme's outstanding shares, valuing the deal at about $17.5bn. Genzyme's board was quick to reject the offer, claiming that it dramatically undervalues the company.

[Ventana] pays $100mm for digital pathology firm [BioImagene]

Sat, 28 Aug 2010 07:57:00 -0400

Supporting its personalized medicine efforts, [Ventana Medical Systems Inc.], a division of [Roche Diagnostics], has paid $100mm for private digital pathology company [BioImagene Inc.]

[Life Technologies] buys [Ion Torrent] for $375mm

Fri, 27 Aug 2010 07:57:00 -0400

[Life Technologies Corp.] is acquiring private DNA sequencing firm [Ion Torrent Systems Inc.] for $375mm in cash and stock. Ion could receive an additional $350mm in cash and shares should certain technical and time-based milestones be met through 2012. The breakdown of the cash versus stock was not disclosed.

[Illumina] buys [Helixis] for $70mm plus earn-outs

Tue, 17 Aug 2010 07:57:00 -0400

Life sciences company [Illumina Inc.] has acquired privately held molecular diagnostics start-up [Helixis Inc.] for $70mm in cash up front and an additional $35mm in potential earn-outs.

[Vivalis] acquires antibody producer [Humalys SAS]

Fri, 02 Jul 2010 07:57:00 -0400

In an effort to broaden its product offerings and improve its bottom line without elevating its risk, [Vivalis] (vaccines and proteins for viral diseases) has acquired fellow French biotech [Humalys SAS], which was founded just three years ago to develop {Humalex}, a technology that identifies and generates human monoclonal antibodies against a therapeutic target or for a diagnostic purpose.

[VaxGen] buys [diaDexus] in reverse merger

Fri, 21 May 2010 08:07:00 -0400

Public cardiovascular therapeutics company [VaxGen Inc.] has agreed to acquire closely held [diaDexus Inc.] (cardiovascular disease diagnostics) in a reverse merger. VaxGen will issue 51.6mm common shares valued at $20.6mm; diaDexus shareholders will then own 60.9% of the combined company.

[PerkinElmer] pays $90mm for [Signature Genomic Laboratories]

Sat, 08 May 2010 08:09:00 -0400

[PerkinElmer Inc.] has agreed to pay $90mm in cash to acquire privately held genetic testing company [Signature Genomic Laboratories LLC].

[Danaher] buys [ITC] from [Thoratec] for $110mm; terminated

Fri, 07 May 2010 08:09:00 -0400

[Thoratec Corp.] has agreed to sell its [International Technidyne Corp.] division (point-of-care diagnostic devices) to [Danaher Corp.] (medical instrumentation) for $110mm in cash. Shareholders may also receive a $26mm earn-out (paid over a three-year-period) based on sales of ITC's alternate site business unit.

[Trinity Biotech] sells coagulation business to [Stago] for $90mm

Fri, 07 May 2010 08:09:00 -0400

[Trinity Biotech PLC] (reagents and instruments for point-of-care and laboratory diagnostics) has sold its global coagulation operations to [Diagnostica Stago] for $90mm. Of the total, $67.5mm was paid up front, and two payments of $11.25mm each will be made on the first and second anniversaries of the deal closing.

[ExonHit] pays $22.5mm up front for [RedPath]; terminated

Wed, 05 May 2010 08:10:00 -0400

[ExonHit Therapeutics SA] (molecular diagnostics and treatments for cancer and CNS diseases) has agreed to acquire privately held US cancer testing company [RedPath Integrated Pathology Inc.] for $12.5mm in cash and $10mm in stock. An additional sales-based earn-out of up to $9.5mm is also possible beginning in 2012.